HONG KONG – South Korea's oldest pharmaceutical company, Yuhan Co. Ltd., has out-licensed its lung cancer drug candidate, lazertinib, to Janssen Pharmaceutica NV in a deal that could involve up to $1.25 billion.

HONG KONG – Undeterred by the underperformance of peers on the Hong Kong Stock Exchange, Suzhou's Cstone Pharmaceuticals Co. Ltd. filed for an IPO on Monday, becoming the 16th biotech company to seek a listing in Hong Kong under the new rules. Proceeds will be used to advance its core asset, CS-1001, aiming to be one of the first PD-L1 antibodies approved in China.

HONG KONG – Undeterred by the underperformance of peers on the Hong Kong Stock Exchange, Suzhou's Cstone Pharmaceuticals Co. Ltd. filed for an IPO on Monday, becoming the 16th biotech company to seek a listing in Hong Kong under the new rules. Proceeds will be used to advance its core asset, CS-1001, aiming to be one of the first PD-L1 antibodies approved in China.

HONG KONG – South Korea's oldest pharmaceutical company, Yuhan Co. Ltd., has out-licensed its lung cancer drug candidate, lazertinib, to Janssen Pharmaceutica NV in a deal that could involve up to $1.25 billion.

HONG KONG – Taiwanese drugmaker Tairx Inc. partnered with its U.S. peer, Biohealth Innovation Inc. (BHI), to set up a joint venture (JV) in the U.S. with the aim of developing what could be the first drug targeting the Nodal protein in cancer.

HONG KONG – Taiwanese drugmaker Tairx Inc. partnered with its U.S. peer, Biohealth Innovation Inc. (BHI), to set up a joint venture (JV) in the U.S. with the aim of developing what could be the first drug targeting the Nodal protein in cancer.